Pharvaris (NASDAQ:PHVS) Shares Climb 7.4% - Time to Buy?

Key Points

• Pharvaris shares rose 7.4% to approximately $29.79 on above-average trading volume, though the stock remains below its 50-day and 200-day moving averages.
• Analyst sentiment is broadly positive: 13 analysts rate the stock Buy, with a consensus “Moderate Buy” rating and an average price target of $58.60.
• The company reported a quarterly EPS loss of $0.81, missing expectations, while insiders sold approximately $18.6 million of stock during the last quarter. Pharvaris is developing oral treatments for hereditary angioedema, led by its candidate deucrictibant.

Pharvaris N.V. (NASDAQ:PHVS - Get Free Report) shares shot up 7.4% on Monday. The company traded as high as $29.79 and last traded at $29.7880. Approximately 555,460 shares were traded during mid-day trading, an increase of 26% from the average session volume of 439,233 shares. The stock had previously closed at $27.74.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on PHVS. HC Wainwright reiterated a "buy" rating on shares of Pharvaris in a report on Tuesday, October 6th. Morgan Stanley raised their price objective on Pharvaris from $46.00 to $62.00 and gave the stock an "overweight" rating in a report on Wednesday, September 9th. Leerink Partners lifted their price objective on Pharvaris from $50.00 to $65.00 and gave the company an "outperform" rating in a research note on Wednesday, September 9th. HSBC raised Pharvaris to an "overweight" rating in a research note on Thursday, August 13th. Finally, Wells Fargo & Company boosted their target price on Pharvaris from $55.00 to $65.00 and gave the stock an "overweight" rating in a report on Wednesday, September 9th. Thirteen research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $58.60.

Pharvaris Trading Up 7.4%

The stock has a market capitalization of $1.95 billion, a PE ratio of -9.74 and a beta of -2.46. The business's 50-day moving average is $34.41 and its two-hundred day moving average is $32.47.

Pharvaris (NASDAQ:PHVS - Get Free Report) last released its quarterly earnings data on Wednesday, August 12th. The company reported ($0.81) EPS for the quarter, missing the consensus estimate of ($0.75) by ($0.06). On average, analysts predict that Pharvaris N.V. will post -3.12 EPS for the current year.

Insider Buying and Selling at Pharvaris

In related news, Director Johannes Gerardus Chri Schikan sold 800 shares of the business's stock in a transaction that occurred on Tuesday, September 22nd. The stock was sold at an average price of $36.19, for a total transaction of $28,952.00. Following the transaction, the director directly owned 115,167 shares of the company's stock, valued at approximately $4,167,893.73. The trade was a 0.69% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, President Peng Lu sold 100,000 shares of the business's stock in a transaction that occurred on Thursday, September 17th. The stock was sold at an average price of $35.00, for a total value of $3,500,000.00. Following the transaction, the president directly owned 64,953 shares in the company, valued at $2,273,355. This trade represents a 60.62% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 513,102 shares of company stock worth $18,643,666.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Engineers Gate Manager LP acquired a new stake in shares of Pharvaris during the second quarter valued at about $1,143,000. Amundi lifted its stake in shares of Pharvaris by 61.4% in the second quarter. Amundi now owns 49,944 shares of the company's stock worth $1,727,000 after acquiring an additional 18,992 shares in the last quarter. Moore Capital Management LP acquired a new position in shares of Pharvaris in the second quarter worth about $1,522,000. Alyeska Investment Group L.P. lifted its stake in shares of Pharvaris by 225.5% in the second quarter. Alyeska Investment Group L.P. now owns 406,829 shares of the company's stock worth $14,068,000 after acquiring an additional 281,829 shares in the last quarter. Finally, Wellington Management Group LLP boosted its holdings in Pharvaris by 12.9% in the second quarter. Wellington Management Group LLP now owns 2,392,934 shares of the company's stock valued at $82,748,000 after purchasing an additional 274,034 shares during the last quarter.

About Pharvaris

Pharvaris N.V. NASDAQ: PHVS is a biopharmaceutical company focused on developing oral therapies for hereditary angioedema (HAE) and other diseases associated with bradykinin-mediated swelling. HAE is a rare genetic disorder that can cause recurring, potentially life-threatening attacks affecting areas such as the skin, gastrointestinal tract and airways.

The company's lead program is deucrictibant, an orally administered small-molecule bradykinin B2 receptor antagonist formerly known as PHA121.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.